Pages
Friday, December 14, 2012
台灣生技沖翻天 !藥華林國鐘低調後 搭上Burrill 要衝了!!!
日本年產 博士2500人 台灣5000人!!
唐湘龍:別躲在學校裡了,快出來吧2012/12/13 09:37 文/唐湘龍 常常看到這一些用來描述生活多麼苦的新聞。多少人去搶多麼少又多麼低薪的工作;多麼老又得出來搶年輕人的飯碗。真慘。前幾天,看到60多歲了,還去爭取林務局巡山員工作。負重賽跑,老先生拿到這份工作。我是很佩服這樣的人。但媒體的調子,只是想拿這種就業媒合場所中最極端的例子來說明:這個社會真慘。是真慘?還是假慘?也有真的。也有假的。假的多。看你在哪個行業。看你想做什麼樣的工作。還有,看你想拿怎樣的薪水。如果你覺得22K快把你悶死了。你想要30K以上的工作。一畢業馬上就有30K。這有什麼難?你不必找我。你到人力銀行網站上去找。你到就業服務處去找。你到馬路上有貼徵人字條的餐廳去找。都有。看你做不做。如果你一畢業,你端著你是個大學生,你要穿西裝打領帶,男生要做助理,女生要當秘書,那是你的選擇。這個選擇裡就包含了22K。供過於求,價格一定下跌。這是常識。常識不會隨著你的主觀意志而移轉。但如果你想生活,你願意吃一點苦,就像那些被描述成到澳洲當台勞的台灣青年,不管在澳洲、在台灣,你都賺得到錢。比22K多得多的錢。但坦白說,就算拿22K吧,也是剛開始的時候。如果進入職場一年,還在22K,那你最好趕快換工作。人力銀行的統計,初次就業者的平均薪資在24K到25K之間。要找22K的,還不是太容易。當然,每個人條件不同。學經歷不同。我真心提個讓人傷心的建議,雖然你應該早就了然於胸。如果你大學指考總分300分不到,我誠心建議你,勉強唸完大學,別再唸什麼研究所了。如果你是總分200分不到,我得更誠心建議你,你最好連大學都別唸了。尤其,不要勉強借錢唸大學。認清自己,找一條不一樣的路。這條路,不必經過大學之門。多數人把不必要的青春以及人生的第一桶金,拿去換一張不值錢的文憑。真不值。我知道這個決定有點難,就看你能不能認清事實。學歷像信用卡,我唸書時,有張普卡,走路就很有風了,金卡是社會地位的象徵。而今,金卡算什麼?白金卡又算什麼?浮濫了。我唸書時,大學錄取率17%,要進台清交,大概都是錄取者更尖端的1%、2%。考上,真是放鞕炮。如果你考上的大學是排名中後段的大學,尤其,如果你選讀的科系,又是文法類科的系所,如果你經濟許可,隨你便。但如果你得自力更生,那相信我,就算了吧。別唸了。早點離開這種混日子、混學歷的升學體系,你一定不會吃虧。你也很可能是郭台銘。我夠老了。老到心裡的Data夠多。坦白說,偉大的企業家幾乎都是黑手起家,偉大的商人幾乎都是業務員起家。你不當黑手,不當業務員,然後就要成功,你是富二代嗎?我唸了台大碩士班,20多年前。那時,碩博士人數少,唸碩博士不但不花錢,政府還每個月給你錢。碩士班每月4K到6K不等,博士班都是10K以上。現在,別說補助,光學費就嚇人。如果你唸的是「重量級學校」,有前景的科系,而且,你真的求知若渴,興味盎然,那就撐著,就唸吧。不然,就快走。如果職場工作一段時間,柳暗花明又一村,覺得自己學然後知不足,要再進修,我不反對。但死命躲在學校裡,不是辦法。以前,研究所學生人數跟大學部學生人數的比例可能1比20都不到。現在,差不多快1比1了。大學浮濫,研究所更浮濫。大部份年輕人唸研究所,只是幫忙學校不倒,幫忙教授就業,幫不到自己什麼。頂多一張不值錢的文憑。以最高階的博士生為例好了,日本的人口數是台灣五倍,但日本一年拿到博士學位的人數只有2500人左右,台灣呢?台灣快5000人。台灣的研究生量產,你不能不盤算,碩士2~3年,博士4~6年。唸完都30了。男生還得當兵,女生連最適生育的年齡都快過了,划不划得來?不要逃避社會壓力,在學校躲越久,社會生存力越差。除非對知識工作真的很感興趣,不然,別急著唸研究所。連大學都不必急著唸。台灣就業問題、薪資問題,是兩個問題擠出來的。一個,是產業結構問題,一個,是人力結構問題。產業在萎縮,人力在膨脹,「薪情」會好才有鬼。產業結構不是你想改就改得了的,但人力結構你比較有調整空間。數字已經告訴你,30年前是高學歷,低失業。慢慢變成現在高學歷,高失業。你還盲目追求高學歷幹什麼。何況,那張文憑值多少錢?你的老闆一眼就看穿。看不穿,試用你三個月,大概也什麼都知道了。你何必打腫臉充博士?再說個數字,就業市場很明顯,年紀越大,失業率越低。40歲以上,失業率大概都在3%以下。60歲以上,甚至不到2%。這跟20到25歲之間,平均10%以上的失業率,天壤之別。這顯示年輕人在有了虛幻的高學歷之後,就很容易出現「高不成,低不就」的情況。一心想找「像個大學畢業生」的「高薪、白領」工作,真難。別太相信台灣媒體的的報導。媒體習慣用簡化而且極端的方式描述社會現象。會被搶得很兇的工作,不是高薪,像空服員。就是保障,像公務員。公職考試人數破表,不只是為了「工」作,更多是為了「公」作。是因為「公」,不只是「工」。那位60出頭的巡山員,不是新人。他以前就是巡山員,現在回鍋。回鍋的原因,一是喜歡,二是保障。我和巡山員入山工作過,簡單工具,一入山可能好幾天。給你30K,你做嗎?
因華&Akorn 合作品項增加 !!
因華明年Q4可望轉盈;口服劑型授權進度受關注 精實新聞 2012-12-14 09:58:24 記者 蕭燕翔 報導 新藥公司因華(4172)今年8月顯影劑嘉多視健與美廠Akorn簽訂藥品授權及供應合約,近日再增新品項,合作品項增至8個,整體簽約金及里程碑金(Milestone),將分三年入帳,首筆可望在明年初入帳。法人也估計,在顯影劑授權金入帳,及普癌汰、倍特寧等銷售成長下,明年第四季起可望轉虧為盈,而口服劑型Gemcitabine最快明年下半年將有對外授權機會。因華指出,此次補充公告與Akron的合約,只是增加品項,目前雙方合作的品項提高至8項,整體簽約金及里程碑金上看1.2億元,分三年入帳,首筆金額預期將在明年初進帳。 另一顯影劑藥品嘉多明方面,因華表示,今年已取得美國核可,最快明年第四季可望出貨歐盟,比較大的營收貢獻應從2014年開始。在學名藥及代理專利藥方面,因華指出,應用於淋巴癌治療的普癌汰,在與原廠協商後,將調整銷售方式,改由該公司直接銷售予國內醫療院所,再支付推廣金給母公司健喬(4114)。法人也估計,因普癌汰今年10月才正式取得健保藥價,明年銷售可望較今年倍數成長,超過2千萬元。 抗感染的倍特寧部分,法人估計,今年的營收貢獻約400萬元,明年在新增東南亞經銷商、擴大外銷下,營收貢獻可望有五成的年增成長。 法人估計,在簽約金入帳下,最快因華明年6月有機會損益兩平,不過明年該公司也會加碼研發支出,全年研發費用將較今年增加至1.3億元左右,在不考慮其他一次性授權的入帳下,預計單季轉虧為盈的時間點將落在明年第四季。 惟法人也看好因華在Gemcitabine口服劑型的授權機會。該藥品預計明年3、4月完成Phase 1a,進行國外授權,且因該藥物改變傳統針劑的用藥不便性,且可改善口服劑型臨床試驗吸收率低、代謝物標高等結果,深受市場期待。
Taiwan and the Netherlands: A special relationship building in life sciences
(BiotechEast staff)3 December, 2012 Ties between Taiwan and the Netherlands go back a long way; way back in fact to when a Dutch colonial government ruled the island from 1624 to 1662. Its last stand at Fort Zeelandia at the site of today's Tainan City, falling to General Koxinga's army from China, put an end of 37 years of rule over local aboriginal and Han Chinese inhabitants.Today, relationships happily are on much better terms. Trade and cultural ties between the two nations are strong. Taiwan exports to the Netherlands totaled US$4.6 billion last year, being mostly of consumer electronics goods. From the Netherlands, imports totaled US$2.9 billion in 2011, with more than 450 investment cases in Taiwan with a total investment of over US$18.4 billion to date.In recent years, one industry sector in particular stands out as being the beneficiary of growing cooperation between the two countries and is a refection of a special kind of synergy that has been building. That industry is the life sciences.More and more, Taiwan's drug development and medical devices companies are building research and business ties with their counterparts in the Netherlands. And these are bilateral ties, with benefits being truly two-way. Biotechnology companies from Taiwan have been setting up operations at Holland's Leiden Bio Science Park, and Dutch companies are beginning to look to Taiwan not only as a market in itself and for its position as a potential stepping stone to China and the rest of Asia, but also as a new location for sourcing technology, investment and manufacturing partnerships.With this series of articles we will examine the beginnings of this special relationship, and take a closer look at the appeal of Leiden Bio Science Park and the Taiwan companies and company executives who call it their European home. We'll also examine what Taiwan has to offer Dutch life science companies, and look at some recent deals in this exciting industry space.Perhaps the person who played the earliest and most influential role in developing this relationship was Taiwan scientist Dr. Andrew Wang, currently Distinguished Research Fellow at the Institute of Biological Chemistry, Academia Sinica. Wang is a world-renowned structural biologist with over 400 papers published to his name. He was the first to discover the left-handed 'Z-DNA' form of DNA in 1979, ushering in a new field of novel DNA structures, and also helped understand the structures of many anti-cancer drug-DNA complexes. Wang was also Vice President of Academia Sinica from 2006 to 2011.It's his Z-DNA discovery which has the Dutch connection. Wang explains."I was at MIT as a scientist in the late 1970s, working on structures of nucleic acid, mostly DNA, and the interaction of certain cancers. If you want to do this kind of research, you need DNA material. But at that time it was extremely expensive. One day a biologist came to visit, and discussion got around to talking about DNA material. The biologist was from the University of Leiden in the Netherlands, at the hospital there. He said that they had just recruited a chemist named Jacques van Boom and he was expert at chemical synthesis; in particular, DNA. So we got connected, and I began to interact with this young professor. We asked him to synthesize a number of oligonucleotides, a small fragment of DNA. And low and behold, a month later he came from Leiden to visit us at MIT. He took a vial out of his pocket, saying, 'Here, I have your molecule.'""If you were to buy such an amount at that time, it would cost millions of dollars. He just gave it to us and said, here you are. So we crystallized it and saw the structure, very different from all the other DNA structures. Our DNA was left handed, not right handed."The two scientists wrote a paper about it in 1979 which later was published in the prestigious scientific journals 'Nature' and 'Science'. And the two became good friends."Now it's in every biochemistry textbook, you'll see a left-handed DNA. We called it Z-DNA. I made my fame out of that. And Jacques van Boom also at the same time became famous in Holland and in Europe, all because of the discovery of this Z-DNA."Wang eventually joined Van Boom and his group in the Netherlands, spending six months at his lab at the University of Leiden, learning how to synthesize DNA.Back then Leiden was just a small town, recalled Wang."It was all just canals and farms, nothing much there. But in the late 80s, they began to build the Leiden Bio Sciences Park. Now there's a lot of life science research going on. The level of chemistry there is very good, in large part from Jacques van Boom's fame and influence. He trained many students who went on to become famous themselves."Wang went back to the US and continued his remarkable career, but returned for another six-month visit in 1995, although to a different town, Nijmegen.As time passed, Wang still kept up his ties with the Netherlands, visiting van Boom yearly until his friend passed away in 2004.Wang has fond memories of his time there, and to this day he retains his connections to the country. This year for example Wang joined the Taiwan biotechnology delegation to visit Leiden Bio Science Park in May. The delegation was led by the Ministry of Economic Affairs, (MOEA) and organized by the Development Center for Biotechnology (DCB).The park is now an impressive resource, says Wang."In Taiwan we don't have this kind of park, but that's the kind of facility we are aiming for with our new life science park at Academia Sinica [the National Biotechnology Research Park, completion expected in 2016]. We want it to house some 200 incubator companies. Right now, we do have an incubator center but it only houses about dozen companies."Dr. Nettie Buitelaar, director of the Leiden Bio Science ParkReflecting on the differences between the academic culture of Holland and Taiwan, Wang mentioned that although there are only a handful of universities, standards are high."They are just as smart as we are, but they are more practical. I feel their training is down to earth, solid. They don't have a lot of exams, but that doesn't matter. In nuclear magnetic resonance, for example, Holland is a very tiny country but their research is ranked among the top five. So they specialize at certain things and they are very good at that."Although Academia Sinica and Leiden Bio Science Park have no formal cooperation agreement or structure in place, Wang thinks this should be a goal to pursue."The last time we visited the Leiden park, the reaction was quite positive. There is a good synergy."
Leiden Bio Science Park We caught up with Dr. Nettie Buitelaar, director of the Leiden Bio Science Park, during her recent visit to Taiwan for the BioBusiness Asia conference. We asked her to introduce the park and expand on the Taiwan connection."The park started in 1984, and is one of the oldest of its kind in the Netherlands. It began when there was suddenly a lot of land available at the university hospital, once the hospital got some new buildings. An entrepreneurial-minded professor persuaded the local government to turn this into a biotech-focused science park, which at the time was very visionary.""In the beginning it didn't take off very fast. But recently we've really been growing. We have now over 100 companies in the science park, most of them focusing on drug development. And we house the most publically listed companies of any science park in the country. If you want to be serious about biotech, you should be in our park."Buitelaar has built strong friendships with Taiwan and the Taiwanese, having visited the island many times."First time I visited, I remember thinking what a pleasant surprise to see how developed the country is, how western the way of doing business is, as compared to China for instance, or to other Asian countries.""And also how eager they are to go to Europe. But what I also noticed is that for Taiwanese companies they see Europe as such a labyrinth; many different countries, many different languages, different regulations to bring your product to the market. So they have no clue how to start there. Luckily, we have lots of service companies in the science park that can help firms bring their products to the European market."Taiwan Liposome Company (TLC) was the first company from Taiwan to set up an office at the park, in 2008. Another firm, Aeon Astron, subsidiary of Taiwan's Body Organ Biomedical Corp, a collagen implant and devices company, set up their office the same year, partly to be closer to the university hospital and its famed ophthalmology department.Buitelaar listed off features of the park that make it particularly attractive to Taiwan companies."First of all we are very close to Amsterdam Airport, which has a direct flight to Taiwan via national carrier KLM. It's a 12-hour direct flight. It sounds very simple, but it makes all the difference. And the airport is only 15 minutes by train from our park. Companies do consider this a great benefit. Biotech is so international. So it's people that travel, it's goods that travel ... So, that's one advantage," she said.Another is that Holland offers a lot of tax advantages, particularly with regard to taxing intellectual property assets. This is a significant benefit and many big international companies put their European central office there because of it.And there's a very international flavor at the park. Around 25 percent of the companies housed there are from outside the Netherlands."And we have more than 1,500 people from overseas working in the park. Many work in the university, as the science faculty and the university hospital are also located in our park. So, that's also another advantage; it's a mixture of academics and industry."Mr. Hans Fortuin, Representative of the Netherlands Trade and Investment Office (NTIO) in TaiwanMemorandum of Understanding sets framework for further cooperation With the signing on February 11, 2011, of a 'Memorandum of Understanding' (MOU) between the Department of Industrial Technology, MOEA of Taiwan and the NL Agency of the Netherlands, on bilateral cooperation in research and the development in innovative technologies, business between the two small countries can only get stronger.Mr. Hans Fortuin, Representative of the Netherlands Trade and Investment Office (NTIO) in Taiwan, elaborated on the significance of the MOU."Actually, Taiwan and the Netherlands have enjoyed excellent business relations for a long time. Electronics giant Philips for example invested in [Taiwan's famed semiconductor firm] TSMC in the 1980s. And ASML, a company that makes equipment used in the semiconductor manufacturing industry, is now the Netherlands' biggest investor in Taiwan.""The MOU is not a purpose in itself. It is an instrument to bring together market partners, research institutes, companies, government people. And there we have been quite successful," he said.And the key for both sides to find specific areas of mutual interest."I think Taiwan and the Netherlands need to find each others' comparative advantages. Where are our niches? Because generic trade promotion does not work anymore, we now need tailor-made approaches. Where are we strong? Where is there a demand in the market? And vice versa. A mutual interest."The MOU has provided a framework for both sides to build on existing connections in technology-based industries, with the agreement specifically focusing on the life sciences, green energy and high tech materials sectors. Since it was signed, both sides have been increasing the frequency of their technical exchanges, and life sciences in particular has reaped the benefits.Dr. Daniel Cheng, Vice President, Development Center for Biotechnology, led a delegation on such a technical visit to Leiden Bio Science Park in May of this year.Cheng sees similarities between the two countries. While the Netherlands promotes itself as the gateway to Europe, similarly Taiwan pitches itself as the gateway to China, Cheng noted."Taiwan is also a small country but we too can play an important gateway role. Let's help each other. We can assist companies from the Netherlands get into China, and they can help Taiwanese companies get a foothold in Europe," suggests Cheng."We have other similarities. We both have flexible business cultures, and we love to trade," said Cheng.
ProMetic Achieves $1.0 Million Milestone With Hematech
Dec. 5, 2012, 9:59 a.m. ESTLAVAL, QUEBEC, Dec 05, 2012 (MARKETWIRE via COMTEX) -- ProMetic Life Sciences Inc. CA:PLI -2.63% ("ProMetic" or the "Corporation") announced today the achievement of the first milestone related to the advancement of a plasma-derived biopharmaceutical product targeting a rare medical condition ("Orphan Drug") in partnership with Hematech Biotherapeutics Inc. ("Hematech").The $1.0 million milestone payment is part of an overall $10 million drug licensing and development agreement concluded with Hematech in May, 2012, of which $1.0 million was already paid to ProMetic as an upfront fee. The agreement calls for additional milestone payments totaling $8.0 million, of which $4 million are expected to be achieved over the course of the next 12 to 15 months.Following the completion of clinical trials and regulatory approval, the Orphan Drug will be commercialized jointly by ProMetic and Hematech on a global basis (excluding China), with both parties sharing profits equally. The Orphan Drug will be manufactured by ProMetic in its Laval, Quebec facility and in HBI's planned facility in Taiwan."We are pleased with the timely achievement of this first milestone. It confirms the potential of our plasma purification manufacturing platform and its related processes to eventually and efficiently produce best-in-class orphan drug products", mentioned Mr. Pierre Laurin, ProMetic's President and Chief Executing Officer. "This milestone achievement bodes well for the advancement of other plasma derived therapeutics currently under development to take place at the future Hematech Taiwanese manufacturing facility", added Mr. Laurin.
About Orphan Drug An orphan drug is a pharmaceutical agent that has been developed specifically to treat a rare medical condition, the condition itself being referred to as an orphan disease. The assignment of orphan status to a disease and to any drugs developed to treat it is a matter of public policy in many countries, and has resulted in medical breakthroughs that may not have otherwise been achieved due to the economics of drug research and development. Orphan drugs generally follow the same regulatory development path as any other pharmaceutical product, in which testing focuses on pharmacokinetics and pharmacodynamics, dosing, stability, safety and efficacy. However, some statistical burdens are lessened in an effort to maintain development momentum.About ProMetic's Plasma Protein Purification System (PPPS(TM))The Plasma Protein Purification System (PPPS(TM)) allows for the targeting and removal of multiple high-value proteins from a single plasma sample at unprecedented activity levels using ProMetic's Mimetic Ligand(TM) adsorbent technology. This system also provides for the recovery of new biotherapeutics as they are discovered and identified. The effect of this process is to reduce the significant losses incurred when using the more conventional Cohn precipitation process.
About Hematech Botherapeutics Inc .Hematech Biotherapeutics Inc. is a privately held biotechnology company with headquarters located in Taipei, Taiwan. Hematech Biotherapeutics Inc. is extensively involved in the sponsorship, development and production of therapeutic drug particularly in the area of hematology. Hematech Biotherapeutics Inc. maintains an extensive collaborative network with industrial partners and is committed to the development of safe, high-quality, and low cost therapeutics. Major shareholders of Hematech Biotherapeutics Inc. include a publicly listed medical service and logistics company in Taiwan.
About ProMetic Life Sciences Inc. ProMetic Life Sciences Inc. ( www.prometic.com ) is a biopharmaceutical company specializing in the research, development, manufacture and marketing of a variety of commercial applications derived from its proprietary Mimetic Ligand(TM) technology. This technology is used in large-scale purification of biologics and the elimination of pathogens. ProMetic is also active in therapeutic drug development with the mission to bring to market effective, innovative, lower cost, less toxic products for the treatment of fibrosis, hematology and cancer. Its drug discovery platform is focused on replacing complex, expensive proteins with synthetic "drug-like" protein mimetics. Headquartered in Laval (Canada), ProMetic has R&D facilities in the UK, the U.S. and Canada, manufacturing facilities in the UK and business development activities in the U.S., Europe and Asia.
進入基藥 以量取勝: 策略之一 !
BCG:陸基層醫療迅速增 2015年達2800億RMB 精實新聞 2012-12-13 12:18:48 記者 戴詩珊 報導 中證網報導,波士頓諮詢(BCG)昨(12)日發佈中國大陸《2009-2011三年醫改對製藥企業的影響》研究報告,預計縣醫院、社區衛生服務中心將成未來大陸醫藥市場最重要的增長點,縣醫院市場規模到十二五末將達2,800億元(人民幣,下同)。 BCG合夥人吳淳指出,如今,大陸約96%的人口擁有公共醫療保險,大陸醫保基金人均支付額在過去三年翻了一倍以上。鑒於這些發展,大陸醫藥市場無疑充滿活力,並有望在未來幾年內繼續擴張。 根據該報告,大陸城市大醫院仍將是製藥企業最重要的競爭之地,目前縣級醫院和社區衛生服務中心對製藥企業的吸引力日益明顯,兩級醫藥市場過去三年的年均成長率達30%以上。報告中指出,面對農村人口看病就醫的大量需求,大陸縣級醫院增長迅速且最具發展潛力。大陸目前擁有約一萬家縣級醫院,這些醫院正日益成為農村人口首次就診和疾病管理的重要管道。而縣級醫院的醫生在藥物選擇以及更改某些疾病的治療方案正發揮著重要的影響力。大陸國家基藥目錄將於2012年底、2013年初擴充。報告中建議,對於有產品進入基藥目錄的跨國企業而言,需要以量取勝。其中關鍵是在潛力最大或招標價格最高的省份獲得市場准入機會。為了取得成功,企業必須明確自身的戰略優勢,並積極影響大陸關鍵省份的基藥招標政策,以便充分發揮自身優勢。同時,企業還應該確定目標省份的優先級,放棄那些潛力小或缺乏客戶關係的省份。